Lee, J., Nair, J., Zimmer, A., Lipkowitz, S., Annunziata, C., Merino, M., … Kohn, E. (2018). Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. The Lancet. Oncology. https://doi.org/10.1016/S1470-2045(18)30009-3 (Original work published 2018)